[go: up one dir, main page]

WO2002047720A3 - Treatment and prevention of ebv infection and ebv-associated disorders - Google Patents

Treatment and prevention of ebv infection and ebv-associated disorders Download PDF

Info

Publication number
WO2002047720A3
WO2002047720A3 PCT/US2001/047885 US0147885W WO0247720A3 WO 2002047720 A3 WO2002047720 A3 WO 2002047720A3 US 0147885 W US0147885 W US 0147885W WO 0247720 A3 WO0247720 A3 WO 0247720A3
Authority
WO
WIPO (PCT)
Prior art keywords
ebv
env
herv
seq
associated disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/047885
Other languages
French (fr)
Other versions
WO2002047720A2 (en
Inventor
Brigitte T Huber
David A Thorley-Lawson
Natalie Sutkowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Priority to US10/432,114 priority Critical patent/US20040096457A1/en
Priority to AU2002230758A priority patent/AU2002230758A1/en
Priority to CA002429755A priority patent/CA2429755A1/en
Priority to JP2002549290A priority patent/JP2004517839A/en
Priority to EP01991002A priority patent/EP1385542A4/en
Publication of WO2002047720A2 publication Critical patent/WO2002047720A2/en
Anticipated expiration legal-status Critical
Publication of WO2002047720A3 publication Critical patent/WO2002047720A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides substances suitable for use as vaccines for the prevention of EBV infection and EBV-associated disorders and methods for administering them. The vaccines are directed against HERV-K18 env (SEQ ID:1) and most preferably comprise antigens obtained from HERV-K18 env. Preferred antigens include SEQ ID:2, SEQ ID:3 and SEQ ID:4. Most preferably, the SAg T cell stimulatory activity of the HERV-K18 env is diminished or eliminated. In another embodiment, the vaccine contains a nucleic acid encoding HERV-K18 env or an immunogenic fragment thereof. The present invention also provides methods for treating EBV infection and EBV-associated disorders.
PCT/US2001/047885 2000-12-11 2001-12-11 Treatment and prevention of ebv infection and ebv-associated disorders Ceased WO2002047720A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/432,114 US20040096457A1 (en) 2001-12-11 2001-12-11 Treatment and prevention of ebv infection and ebv-associated disorders
AU2002230758A AU2002230758A1 (en) 2000-12-11 2001-12-11 Treatment and prevention of EBV infection and EBV-associated disorders
CA002429755A CA2429755A1 (en) 2000-12-11 2001-12-11 Treatment and prevention of ebv infection and ebv-associated disorders
JP2002549290A JP2004517839A (en) 2000-12-11 2001-12-11 Treatment and prevention of EBV infection and EBV-related disorders
EP01991002A EP1385542A4 (en) 2000-12-11 2001-12-11 TREATMENT AND PREVENTION OF EPSTEIN-BARR (EBV) VIRUS INFECTION AND DISORDERS ASSOCIATED WITH IT

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25467300P 2000-12-11 2000-12-11
US60/254,673 2000-12-11

Publications (2)

Publication Number Publication Date
WO2002047720A2 WO2002047720A2 (en) 2002-06-20
WO2002047720A3 true WO2002047720A3 (en) 2003-10-23

Family

ID=22965136

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/047885 Ceased WO2002047720A2 (en) 2000-12-11 2001-12-11 Treatment and prevention of ebv infection and ebv-associated disorders

Country Status (5)

Country Link
EP (1) EP1385542A4 (en)
JP (1) JP2004517839A (en)
AU (1) AU2002230758A1 (en)
CA (1) CA2429755A1 (en)
WO (1) WO2002047720A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002342783A1 (en) * 2001-08-31 2003-03-10 Novimmune S.A. Allelic variants of herv-k18 provirus and their use in analysis
AU2002338856A1 (en) * 2001-09-06 2003-03-24 Novimmune S.A. Peptides derived from the superantigen (sag) env protein of herv-k18 and their use in obtaining sag-inhibitory antibodies and in vaccination against sag
DE102004011564A1 (en) * 2004-03-08 2005-09-29 Rwth Aachen Vaccine for the prevention and / or treatment of a herpes virus infection
DE602005022056D1 (en) * 2004-03-30 2010-08-12 Centre Nat Rech Scient POLYPEPTIDE SEQUENCES INVOLVED IN THE MODULATION OF THE IMMUNOSUPPPRESSIVE EFFECT OF VIRAL PROTEINS
GB0707208D0 (en) * 2007-04-13 2007-05-23 Istituto Superiore Di Sanito Novel disease treatments
CN117656334B (en) * 2024-02-01 2024-04-12 广州市亿安劳保用品有限公司 Glove dipping processing device for glove production line

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858723A (en) * 1995-12-05 1999-01-12 Behringwerke Aktiengesellschaft Polypeptides and antibodies for diagnosing and treating seminoma

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002338856A1 (en) * 2001-09-06 2003-03-24 Novimmune S.A. Peptides derived from the superantigen (sag) env protein of herv-k18 and their use in obtaining sag-inhibitory antibodies and in vaccination against sag

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858723A (en) * 1995-12-05 1999-01-12 Behringwerke Aktiengesellschaft Polypeptides and antibodies for diagnosing and treating seminoma

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CONRAD ET AL.: "A human endogenous retroviral superantigen as candidate autoimmune gene in type I diabetes", CELL, vol. 90, 25 July 1997 (1997-07-25), pages 303 - 313, XP002058200 *
SUTKOWSKI ET AL.: "An Epstein-barr virus-associated superantigen", J. EXP. MED., vol. 184, September 1996 (1996-09-01), pages 971 - 980, XP002909211 *
SUTKOWSKI ET AL.: "Epstein-barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen", IMMUNITY, vol. 15, October 2001 (2001-10-01), pages 579 - 589, XP002909213 *
TONJES ET AL.: "Expression of human endogenous retrovirus type K envelope glycoprotein in insect and mammalian cells", JOURNAL OF VIROLOGY, vol. 71, no. 4, April 1997 (1997-04-01), pages 2747 - 2756, XP002909212 *

Also Published As

Publication number Publication date
EP1385542A4 (en) 2005-11-16
WO2002047720A2 (en) 2002-06-20
AU2002230758A1 (en) 2002-06-24
EP1385542A2 (en) 2004-02-04
JP2004517839A (en) 2004-06-17
CA2429755A1 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
PT1409692E (en) Novel peptides of the respiratory syncytial virus (rsv) g protein and their use in a vaccine
AU7690898A (en) Vectors and methods for immunization or therapeutic protocols
DE69840383D1 (en) CTL EPITOPE OF EPSTEIN-BARR VIRUS
FI102382B1 (en) Expression system for chimeric glycoproteins containing immunogenic fragments of human respiratory syncytial virus glycoproteins
CA2224257A1 (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
NO20091761L (en) Virus vaccine vaccine, method of preparation and use thereof
EP0835133A4 (en) Recombinant poxvirus-rabies compositions and combination compositions and uses
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
WO2002032943A3 (en) Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
WO2000061737A3 (en) Production of attenuated negative stranded RNA virus vaccines
WO2003011893A3 (en) Immunologically significant herpes simplex virus antigens and methods for using same
WO2003059385A3 (en) Hiv vaccine and method of use
HUP9801266A2 (en) Multimeric, recombinant urease vaccine
WO2000061736A3 (en) Recombinant and mutant marek's disease virus
AU2002211095A1 (en) Genetic immunisation against cervical carcinoma
WO2002047720A3 (en) Treatment and prevention of ebv infection and ebv-associated disorders
WO2002022687A3 (en) Viral chemokine-tumur antigen fusion proteins
CA2245545A1 (en) Vaccines against varicella zoster virus gene 63 product
WO1995005460A3 (en) Feline immunodeficiency virus isolate ncsu 1
WO2002040059A3 (en) Methods and compositions for inducing cell-mediated immune responses
MY105313A (en) Malaria vaccine.
BR9909076A (en) Attenuated measles virus, recombinantly generated, isolated, measles virus, human respiratory syncytial virus (rsv), subgroup b, attenuated, recombinantly generated, isolated, rsv, subgroup b, vaccine process for immunizing an individual to induce protection against virus measles, process for immunizing an individual to induce protection against rsv, subgroup b, composition, process for producing attenuated infectious measles virus, process for producing attenuated infectious rsv subgroup b
WO1998023752A3 (en) Papilloma viruses, agents for detecting the same and for treating diseases caused by such viruses
WO2000077177A3 (en) Isolation of a human retrovirus
WO2003045428A3 (en) Use of a technically modified cell as a vaccine for treating tumoral disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002230758

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2429755

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001991002

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002549290

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10432114

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001991002

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001991002

Country of ref document: EP